All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents
Featured:
Mohamad Mohty
Marc BraunsteinDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc Braunstein, NYU Langone Health, New York, US, and Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, about the role of upfront transplant consolidation in the era of novel agents.
ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents
Long-term follow-up data about upfront autologous hematopoietic stem cell transplantation (auto-HSCT) were presented at the 62nd ASH Annual Meeting and Exposition. Mohty and Braunstein agree on the importance of auto-HSCT and on the fact that, when possible, it should not be delayed.
They outline the value of upfront auto-HSCT even in the era of novel agents being developed for multiple myeloma. They also talk about consolidation and maintenance therapy after transplant.
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?